NCT05105243View on ClinicalTrials.gov

Phase 1 SAD/MAD Study of CVN766 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

January 17, 2022

Primary Completion Date

October 30, 2022

Study Completion Date

November 21, 2022

Conditions

Safety IssuesTolerance

Interventions

DRUG

CVN766

highly selective orexin-1 receptor (Ox1R) antagonist

Trial Locations (1)

3004

Nucleus Network, Melbourne

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Cerevance

INDUSTRY